Innovent reports clinical trial results of its anti-PD-1 monoclonal antibody
Sintilimab, the first drug submitted for New Drug Application (NDA) by Innovent Biologics is making quick strides as a first-line of treatment for patients with non-squamous non-small cell lung cancer. …
Read More